SIGN: a Phase II, open-label, randomized study comparing gefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

被引：1
|
作者：
Cufer, T
Vrdoljak, E
机构：
[1] Clin Hosp Split, Split, Croatia
[2] Inst Oncol, Ljubljana, Slovenia
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80403-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [31] Second-line therapy for advanced non-small-cell lung cancer
    Hann C.L.
    Brahmer J.R.
    Current Oncology Reports, 2006, 8 (4) : 243 - 247
  • [32] First-line gefitinib (IRESSA) versus vinorelbine (invite): A randomized phase II study in elderly patients with advanced non-small-cell lung cancer
    Crino, L.
    Zatlouka, P.
    Reck, M.
    Pesek, M.
    Thompson, J. C.
    Forc, H. E. R.
    Ghiorghiu, S.
    Duffield, E. L.
    Armour, A.
    Cullen, M.
    ANNALS OF ONCOLOGY, 2007, 18 : 21 - 22
  • [33] Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer
    Mikio Oka
    Minoru Fukuda
    Seiji Nagashima
    Masaaki Fukuda
    Akitoshi Kinoshita
    Hiroshi Soda
    Seiji Doi
    Fumihiko Narasaki
    Mitsuhiro Suenaga
    Hiroshi Takatani
    Yo-ichi Nakamura
    Shigeru Kawabata
    Junji Tsurutani
    Tetsuro Kanda
    Shigeru Kohno
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 446 - 450
  • [34] Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)
    Douillard, Jean-Yves
    Kim, Edward
    Hirsh, Vera
    Mok, Tony
    Socinski, Mark
    Gervais, Radj
    Wu, Yi-Long
    Li, Longyun
    Sellers, Mark
    Lowe, Elizabeth
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S305 - S306
  • [35] Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial
    Pectasides, D
    Pectasides, M
    Farmakis, D
    Kostopoulou, V
    Nikolaou, M
    Gaglia, A
    Koumpou, M
    Mylonakis, N
    Xiros, N
    Economopoulos, T
    Raptis, SA
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 294 - 299
  • [36] An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Waller, Cornelius F.
    Vynnychenko, Ihor
    Bondarenko, Igor
    Shparyk, Yaroslav
    Hodge, Jeffrey P.
    Freeman, Anne
    Huber, Brian
    Lieberman, Ronald
    Shelton, Mark J.
    Dave, Harish
    CLINICAL LUNG CANCER, 2015, 16 (02) : 92 - 99
  • [37] Gefitinib (IRESSA) versus vinorelbine in chemonaive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study
    Crino, Lucio
    Zatloukal, Petr
    Reck, Martin
    Pesek, Milos
    Thomson, Joyce
    Ford, Hugo
    Hirsch, Fred
    Duffield, Emma
    Armour, Alison
    Cullen, Michael
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S341 - S341
  • [38] Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
    Manegold, Christian
    Vansteenkiste, Johan
    Cardenal, Felipe
    Schuette, Wolfgang
    Woll, Penella J.
    Ulsperger, Ernst
    Kerber, Anne
    Eckmayr, Josef
    von Pawel, Joachim
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 175 - 182
  • [39] Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
    Christian Manegold
    Johan Vansteenkiste
    Felipe Cardenal
    Wolfgang Schuette
    Penella J. Woll
    Ernst Ulsperger
    Anne Kerber
    Josef Eckmayr
    Joachim von Pawel
    Investigational New Drugs, 2013, 31 : 175 - 182
  • [40] Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
    Vergnenegre, Alain
    Monnet, Isabelle
    Ricordel, Charles
    Bizieux, Acya
    Curcio, Hubert
    Bernardi, Marie
    Corre, Romain
    Guisier, Florian
    Hominal, Stephane
    Le Garff, Gwenaelle
    Bylicki, Olivier
    Locher, Chrystele
    Geier, Margaux
    Chouaid, Christos
    Robinet, Gilles
    LUNG CANCER, 2023, 178 : 191 - 197
12345